Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: Role of phosphodiesterase 3

British Journal of Pharmacology

Volumn 119, Issue 3, 1996, Pages 471-478

  Delpy, Eric ^a   Coste, Hervé ^a   Le Monnier De Gouville, Anne Charlotte ^a  

^a Laboratoire GlaxoWellcome   (France)

Author keywords

1,3 dimethyl 6 (2 propoxy 5 methane sulphonylamidophenyl) ; Cyclic AMP; Cyclic GMP; Endothelium; Isoprenaline; Phosphodiesterase (PDE) inhibitors; pyrazolo 3,4 d pyrimidin 4 (5h) one (DMPPO); Relaxation; Smooth muscle cells

Indexed keywords

ARGININE METHYL ESTER; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; ISOPRENALINE; METHYLENE BLUE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHODIESTERASE; ROLIPRAM;

ANIMAL CELL; ANIMAL TISSUE; AORTA MEDIA; ARTERY ENDOTHELIUM; ARTICLE; DRUG POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE RELAXATION;

EID: 0029816157     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15696.x     Document Type: Article

References (34)

1. ANAND-SRIVASTAVA, M.B. & TRACHTE, G.J. (1993). Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol. Rev., 45, 455-497.
2. BEAVO, J. (1990). Multiple phosphodiesterase isozymes: background, nomenclature and implications. In Molecular Pharmacology of Cell Regulation, ed. Beavo J & Houslay M.D. Vol. 2, pp. 3-14, Chichester: John Wiley & Sons Ltd.
3. BUXTON, I.L.O. & BRUNTON, L.L. (1983). Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem., 258, 10233-10239.
4. CHAMLEY, J.H., CAMPBELL, G.R. & MCCONNELL, J.D. (1977). Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tiss. Res., 177, 503-522.
5. 2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic dependent protein kinase. J. Biol. Chem., 264, 1146-1155.
6. COSTE, H. & GRONDIN, P. (1995). Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol., 50, 1577-1585.
7. DELPY, E. & LE MONNIER DE GOUVILLE, A.C. (1996). Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. Br. J. Pharmacol., (in press).
8. DUMAÎTRE, B.A. & DODIC, N. (1995). New pyrazolopyrimidine derivatives inhibit cyclic guanosine 3′ 5′-monophosphate specific phosphodiesterase-useful for treating angina, hypertension, congestive heart failure, renal failure, atherosclerosis etc. Patent Application, EP-636626-A1.
9. FREDHOLM, B.B. & SOLLEVI, A. (1986). Cardiovascular effects of adenosine. Clin. Physiol., 6, 1-21.
10. GARBERS, D.L. (1989). Guanylate cyclase, a cell surface receptor. J. Biol. Chem., 264, 9103-9106.
11. GERZER, R., HOFMAN, F. & SCHULZ, G. (1981). Purification of a soluble, sodium nitroprusside-stimulated guanylate cyclase from bovine lung. Eur. J. Biochem., 116, 479-486.
12. GRACE, G.C., MACDONALD, P.S. & DUSTING, G.J. (1988). Cyclic nucleotide interactions involved in endothelium-dependent dilatation in rat aortic rings. Eur. J. Pharmacol., 148, 17-24.
13. GRAIER, W.F., GROSCHNER, K., SCHMIDT, K. & KUKOVETZ, W.R (1992). Increases in endothelial cyclic AMP levels amplify agonist-induced formation of endothelium-derived relaxing factor (EDRF). Biochem. J., 288, 345-349.
14. GRAY, D.W. & MARSHALL, I. (1992). Novel signal transduction pathway mediating endothelium-dependent β-adrenoceptor vasorelaxation in rat thoracic aorta. Br. J. Pharmacol., 107, 684-690.
15. 1. J. Biol. Chem., 255, 5113-5119.
16. 2+ transients. Circ. Res., 69, 1369-1379.
17. JANG, E.K., DAVIDSON, M.M.L., CRANKSHAW, D. & HASLAM, R.J. (1993). Synergistic inhibitory effects of atriopeptin II and isoprenaline on contraction of rat aortic smooth muscle: roles of cyclic GMP and cyclic AMP. Eur. J. Pharmacol., 250, 477-481.
18. KOMAS, N., LUGNIER, C. & STOCLET, J.C. (1991). Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitor. Br. J. Pharmacol., 104, 495-503.
19. KUHN, M., OTTEN, A., FRÖLICH, J.C. & FÖRSTERMANN, U. (1991). Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor nitric oxide from bovine aortic endothelial cells. J. Pharmacol. Exp. Ther., 256, 677-682.
20. KUKOVETZ, W.R., POCH, C. & HOLTZMANN, S. (1981). Cyclic nucleotides and relaxation of vascular smooth muscle. In Vasodilation. ed. Vanhoutte, P.M. & Leuzen, I. pp. 339-353. New York: Raven Press.
21. 2+ by cyclic AMP in vascular smooth muscle cells. Am. J. Physiol., 258 (Cell. Physiol., 27), C399-C407.
22. LUGNIER, C. & KOMAS, N. (1993). Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation. Eur. Heart J., 14 (suppl 1), 141-148.
23. LUS̈CHER, T. (1991). Endothelium-derived nitric oxide - The endogenous nitrovasodilator in the human cardiovascular system. Eur. Heart J., 12, 2-11.
24. MACDONALD, P.S., DUBBIN, P.N. & DUSTING, G.J. (1987). β-Adrenoceptors on endothelial cells do not influence release of relaxing factor in dog coronary arteries. Clin. Exp. Pharmacol. Physiol., 14, 525-534.
25. MANGANIELLO, V.C., MURATA, T., TAIRA, M., BELFRAGE, P. & DEGERMAN, E. (1995). Diversity in cyclic nucleotide phosphodiesterase isozyme families. Arch. Biochem. Biophys., 322, 1-13.
26. MAURICE, D.H., CRANKSHAW, D. & HASLAM, R.J. (1991). Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur. J. Pharmacol., 192, 235-242.
27. MAURICE, D.H. & HASLAM, R.J. (1990). Molecular basis of the Synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol., 37, 671-681.
28. MULLER, B., STOCLET, J.C. & LUGNIER, C. (1992). Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles. Eur. J. Pharmacol., 225, 263-272.
29. MURAD, F. (1986). Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest., 78, 1-5.
30. MURRAY, K.J. (1990). Cyclic AMP and mechanism of vasodilation. Pharmacol. Ther., 47, 329-345.
31. 2-receptors and molecular mechanisms in platelet and vasculature: state of the art. Pharmacol. Res. Commun., 19, 735-769.
32. REEVES, M.L., LEIGH, B.K. & ENGLAND, P.J. (1987). The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J., 241, 535-541.
33. SATAKE, N., ZHOU, Q., MORIKAWA, M., INOUE, M. & SHIBATA, S. (1995). Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoprenaline in isolated rat aorta: involvement of cyclic GMP-inhibilable cyclic AMP phosphodiesterase. J. Cardiovasc. Pharmacol., 25, 489-494.
34. SONNENBURG, W.K. & BHAVO, J.A. (1994). Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv. Pharmacol., 26, 85-114.